Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 4
1991 2
1992 1
1993 5
1994 2
1995 5
1996 3
1997 3
1998 3
1999 3
2000 2
2001 6
2002 7
2003 10
2004 5
2005 7
2006 11
2007 11
2008 6
2009 6
2010 7
2011 13
2012 14
2013 4
2014 7
2015 11
2016 13
2017 22
2018 17
2019 16
2020 22
2021 19
2022 18
2023 19
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Results by year

Filters applied: . Clear all
Page 1
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB, Asahina A, Coates LC, Landewé R, Merola JF, Ritchlin CT, Tanaka Y, Gossec L, Gottlieb AB, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Mease PJ. McInnes IB, et al. Among authors: asahina a. Lancet. 2023 Jan 7;401(10370):25-37. doi: 10.1016/S0140-6736(22)02302-9. Epub 2022 Dec 6. Lancet. 2023. PMID: 36493791 Free article. Clinical Trial.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Gottlieb AB, Thaçi D, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Coates LC. Merola JF, et al. Among authors: asahina a. Lancet. 2023 Jan 7;401(10370):38-48. doi: 10.1016/S0140-6736(22)02303-0. Epub 2022 Dec 6. Lancet. 2023. PMID: 36495881 Free article. Clinical Trial.
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
Papp K, Warren RB, Green L, Reich K, Langley RG, Paul C, Asahina A, Johnson L, Arora V, Osuntokun O, Lebwohl M. Papp K, et al. Among authors: asahina a. Lancet Rheumatol. 2023 Sep;5(9):e542-e552. doi: 10.1016/S2665-9913(23)00120-0. Epub 2023 Aug 21. Lancet Rheumatol. 2023. PMID: 38251498 Clinical Trial.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ritchlin CT, Coates LC, McInnes IB, Mease PJ, Merola JF, Tanaka Y, Asahina A, Gossec L, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Landewé RB. Ritchlin CT, et al. Among authors: asahina a. Ann Rheum Dis. 2023 Nov;82(11):1404-1414. doi: 10.1136/ard-2023-224431. Epub 2023 Sep 11. Ann Rheum Dis. 2023. PMID: 37696588 Free PMC article. Clinical Trial.
Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events.
Katsuta M, Kimura T, Tashiro K, Murakami M, Hata K, Yanagisawa T, Onuma H, Yamamoto T, Sugaya S, Watanabe Y, Nobeyama Y, Egawa S, Asahina A. Katsuta M, et al. Among authors: asahina a. Anticancer Res. 2022 Apr;42(4):2023-2028. doi: 10.21873/anticanres.15682. Anticancer Res. 2022. PMID: 35347024
The nose as a predilection site of pemphigus.
Aizawa N, Asahina A, Ishii N, Hashimoto T, Nakagawa H. Aizawa N, et al. Among authors: asahina a. Clin Exp Dermatol. 2018 Jan;43(1):71-72. doi: 10.1111/ced.13275. Epub 2017 Oct 12. Clin Exp Dermatol. 2018. PMID: 29027253 No abstract available.
270 results